Current approaches to diagnosis and treatment of invasive aspergillosis

Area of Science:

• Medical Mycology
• Infectious Diseases
• Immunology

Background:

• Filamentous fungi (moulds) are common environmental fungi that can cause severe respiratory infections, particularly invasive aspergillosis in immunocompromised patients.
• Invasive aspergillosis is a significant cause of illness and death, especially in individuals with neutropenia, transplant recipients, advanced AIDS, or chronic granulomatous disease.
• The sinopulmonary tract is the most common site of infection due to inhalation of fungal spores.

Purpose of the Study:

• To review the current understanding and management of invasive aspergillosis.
• To highlight advancements in antifungal therapies and diagnostic tools.
• To discuss emerging strategies for treating this life-threatening infection.

Main Methods:

• Review of current medical literature on invasive aspergillosis.
• Analysis of clinical trial data on antifungal efficacy.
• Discussion of diagnostic advancements and immunological insights.

Main Results:

• Voriconazole, a second-generation triazole, has emerged as superior to conventional amphotericin B and is the current standard of care.
• Combination antifungal therapy, particularly echinocandin with azoles or amphotericin B, is under active investigation.
• Advances in diagnostic methods like antigen detection and PCR aid in early diagnosis, though limitations exist.

Conclusions:

• The antifungal armamentarium for invasive aspergillosis has expanded significantly, addressing an unmet need.
• Voriconazole represents a major therapeutic advance, establishing a new standard of care.
• Future directions include combination therapies and novel immune augmentation strategies, with promising preclinical data.